Good Start Genetics is setting the new gold standard in carrier screening by making testing for the most comprehensive set of known and novel disease-causing mutations accessible for routine clinical practice. After years of development and rigorous validation, Good Start Genetics has harnessed the power of next-generation sequencing and other best-in-class technologies to provide highly accurate, actionable, and affordable tests for all ACOG and ACMG recommended disorders. For these reasons, fertility specialists and their patients can have a high degree of confidence in their carrier screening results, and no longer have to compromise accuracy for price.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
04/02/12 | $14,000,000 | Series B |
OrbiMed Advisors Safeguard Scientifics | undisclosed |
05/08/13 | $28,000,000 | Venture Debt |
Capital Royalty | undisclosed |